Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR.

Oncotarget. 2010 Sep;1(5):329-38.

2.

Regulation of Immunity by Butyrophilins.

Rhodes DA, Reith W, Trowsdale J.

Annu Rev Immunol. 2016 May 20;34:151-72. doi: 10.1146/annurev-immunol-041015-055435. Epub 2016 Jan 11. Review.

PMID:
26772212
3.

The role of B7 costimulation in T-cell immunity.

Harris NL, Ronchese F.

Immunol Cell Biol. 1999 Aug;77(4):304-11. Review.

PMID:
10457196
4.

Antigen-presenting cell (APC) subsets in ovarian cancer.

Wilke CM, Kryczek I, Zou W.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):120-6. doi: 10.3109/08830185.2011.567362. Review.

PMID:
21557638
5.

Could B7-H4 serve as a target to activate anti-cancer immunity?

Wang L, Heng X, Lu Y, Cai Z, Yi Q, Che F.

Int Immunopharmacol. 2016 Sep;38:97-103. doi: 10.1016/j.intimp.2016.05.020. Epub 2016 Jun 1. Review.

PMID:
27258187
6.

Inhibitory costimulation and anti-tumor immunity.

Martin-Orozco N, Dong C.

Semin Cancer Biol. 2007 Aug;17(4):288-98. Epub 2007 Jun 23. Review.

7.

Regulation of costimulation in the era of butyrophilins.

Arnett HA, Escobar SS, Viney JL.

Cytokine. 2009 Jun;46(3):370-5. doi: 10.1016/j.cyto.2009.03.009. Epub 2009 Apr 19. Review.

PMID:
19380239
8.

Immune modulation by butyrophilins.

Arnett HA, Viney JL.

Nat Rev Immunol. 2014 Aug;14(8):559-69. doi: 10.1038/nri3715. Review.

PMID:
25060581
9.

Butyrophilins: an important new element of resistance.

Malinowska M, Tokarz-Deptuła B, Deptuła W.

Cent Eur J Immunol. 2017;42(4):399-403. doi: 10.5114/ceji.2017.72806. Epub 2017 Dec 30. Review.

10.

Butyrophilins: an emerging family of immune regulators.

Abeler-Dörner L, Swamy M, Williams G, Hayday AC, Bas A.

Trends Immunol. 2012 Jan;33(1):34-41. doi: 10.1016/j.it.2011.09.007. Epub 2011 Oct 24. Review.

PMID:
22030238
11.

Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.

Okła K, Wertel I, Polak G, Surówka J, Wawruszak A, Kotarski J.

Int Rev Immunol. 2016 Sep 2;35(5):372-385. Epub 2016 Sep 19. Review.

PMID:
27644763
12.

Tumor-derived factors affecting immune cells.

Russo V, Protti MP.

Cytokine Growth Factor Rev. 2017 Aug;36:79-87. doi: 10.1016/j.cytogfr.2017.06.005. Epub 2017 Jun 8. Review.

PMID:
28606733
13.

Tumor-host interactions: the role of inflammation.

Le Bitoux MA, Stamenkovic I.

Histochem Cell Biol. 2008 Dec;130(6):1079-90. doi: 10.1007/s00418-008-0527-3. Epub 2008 Oct 25. Review.

PMID:
18953558
14.

The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response.

Afrache H, Gouret P, Ainouche S, Pontarotti P, Olive D.

Immunogenetics. 2012 Nov;64(11):781-94. doi: 10.1007/s00251-012-0619-z. Epub 2012 Sep 23. Review.

PMID:
23000944
15.

Lesser-Known Molecules in Ovarian Carcinogenesis.

Lozneanu L, Cojocaru E, Giuşcă SE, Cărăuleanu A, Căruntu ID.

Biomed Res Int. 2015;2015:321740. doi: 10.1155/2015/321740. Epub 2015 Aug 3. Review.

16.

The immune system in the pathogenesis of ovarian cancer.

Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS.

Crit Rev Immunol. 2013;33(2):137-64. Review.

17.

The Microenvironmental Landscape of Brain Tumors.

Quail DF, Joyce JA.

Cancer Cell. 2017 Mar 13;31(3):326-341. doi: 10.1016/j.ccell.2017.02.009. Review.

Supplemental Content

Support Center